Key Points
- Director Keith Meister sold 283,269 Illumina shares at an average price of $199.61, generating approximately $56.5 million and reducing his ownership by 11.94% to 2.09 million shares.
- Illumina exceeded quarterly expectations with $1.31 in adjusted EPS and $1.16 billion in revenue, up 9.4% year over year; management guided to fiscal 2026 EPS of $5.30–$5.40.
- Analyst sentiment remains mixed: several firms raised price targets and maintained bullish ratings, but the consensus rating is “Hold” with a $188.40 target, while Bank of America reiterated a “Sell” rating and $140 target over demand concerns.
Illumina, Inc. (NASDAQ:ILMN - Get Free Report) Director Keith Meister sold 283,269 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $199.61, for a total transaction of $56,543,325.09. Following the completion of the transaction, the director owned 2,089,425 shares in the company, valued at $417,070,124.25. This represents a 11.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Illumina Price Performance
ILMN opened at $193.72 on Friday. The company has a fifty day moving average price of $180.63 and a two-hundred day moving average price of $148.77. The firm has a market capitalization of $29.25 billion, a PE ratio of 36.14, a P/E/G ratio of 2.81 and a beta of 1.45. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $207.00. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.
Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm's quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current year.
Wall Street Analyst Weigh In
Several analysts recently commented on ILMN shares. Royal Bank Of Canada raised their price objective on Illumina from $170.00 to $230.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. Evercore restated an "outperform" rating on shares of Illumina in a report on Monday, July 6th. Zacks Research raised Illumina from a "hold" rating to a "strong-buy" rating in a research report on Monday. Stifel Nicolaus lifted their price objective on Illumina from $155.00 to $225.00 and gave the company a "buy" rating in a report on Friday, July 31st. Finally, Guggenheim increased their target price on Illumina from $200.00 to $226.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $188.40.
Check Out Our Latest Analysis on Illumina
Institutional Trading of Illumina
Several hedge funds and other institutional investors have recently modified their holdings of the company. Impact Partnership Wealth LLC grew its holdings in shares of Illumina by 235.8% during the first quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company's stock worth $1,366,000 after buying an additional 7,780 shares in the last quarter. SG Americas Securities LLC lifted its stake in Illumina by 8.0% in the 1st quarter. SG Americas Securities LLC now owns 86,318 shares of the life sciences company's stock valued at $10,640,000 after acquiring an additional 6,425 shares in the last quarter. Louisiana State Employees Retirement System bought a new stake in Illumina in the 1st quarter valued at approximately $5,460,000. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in Illumina by 27.4% during the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 348,011 shares of the life sciences company's stock worth $45,645,000 after acquiring an additional 74,900 shares during the last quarter. Finally, New York State Teachers Retirement System boosted its position in Illumina by 2.7% during the 4th quarter. New York State Teachers Retirement System now owns 149,638 shares of the life sciences company's stock worth $19,627,000 after acquiring an additional 4,002 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.
Key Headlines Impacting Illumina
Here are the key news stories impacting Illumina this week:
- Positive Sentiment: Zacks upgraded Illumina from “hold” to “strong buy,” citing favorable momentum characteristics. The company has also benefited from strong clinical momentum and continued leadership in genomic sequencing. Why Illumina Is a Strong Momentum Stock
- Positive Sentiment: Piper Sandler reiterated an “overweight” rating, while TD Cowen maintained its “hold” rating. The mixed views indicate some analysts remain constructive on Illumina’s longer-term opportunity despite near-term concerns. Piper Sandler Reiterates Overweight Rating
- Neutral Sentiment: Illumina’s recent earnings showed revenue growth and an EPS beat, but investors remain focused on the sustainability of demand and whether growth can justify the stock’s elevated valuation following its strong 52-week advance.
- Negative Sentiment: Director Keith A. Meister sold approximately 741,000 Illumina shares across August 4 and 5 for a combined value of about $148.2 million, reducing his holdings by roughly 28% over the two transactions. Although he still owns more than 2 million shares, the large sales may weigh on investor sentiment. Illumina Insider Trading Filing
- Negative Sentiment: Bank of America Securities reiterated a “sell” rating and a $140 price target, arguing that a one-time consumables benefit is masking weak underlying demand. The target is substantially below recent trading levels, reinforcing concerns about near-term operating momentum. Bank of America Maintains Sell Rating on Illumina
Illumina Company Profile
(
Get Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
